The transformative phase of capital raising that Scancell has undertaken to date in 2020 now appears to have drawn to a close.

The transformative phase of capital raising that Scancell has undertaken to date in 2020 now appears to have drawn to a close.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS
Convertible loan fully repaid, further opex reductions and new HH-1 intervention via £4.2m placing